Home › All Companies › BDSX › Annual Report

BIODESIX INC (BDSX) — Annual Report

AI-Powered SEC Filing Analysis

← All BDSX filings
Latest Annual Report Filed: 2026-02-26

Key Insights

  • The company reported a significant increase in revenue, driven by strong growth in its diagnostic tests business.
  • Margins have been under pressure due to rising costs, which could impact profitability going forward.
  • The company has secured a new licensing agreement with BioRad, which could expand its product portfolio and open up new market opportunities.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for BIODESIX INC

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.